Representative before the EPO

Technology company logo thumb
no operation time available
3 offices
Technology Company

We have observed 32 EP applications David O'Connor has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after December 17, 2012). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP11713416

ANTIBODIES AGAINST CSF-1R

IPC classification:
A61K 39/395, A61P 35/00, A61P 35/02, C07K 16/28, C07K 16/32
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
The patent has been granted
EP11792989

CGRP ANTIBODIES

IPC classification:
A61K 39/395, C07K 16/26
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
The patent has been granted
EP12712874

VARIANTS OF HUMAN GDNF

IPC classification:
A61K 38/18, C07K 14/475
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
EXAMINATION IN PROGRESS
EP12766847

FIBROBLAST GROWTH FACTOR 21 VARIANTS

IPC classification:
A61K 38/18, C07K 14/50
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12795981

ANTI-GLUCAGON ANTIBODIES AND USES THEREOF

IPC classification:
C07K 16/26
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13157487

Novel imaging agents for detecting neurological dysfunction

IPC classification:
C07B 59/00
Applicant:
Eli Lilly and Company Limited
Applicant:
Siemens Molecular Imaging, Inc.
Agent:
Olaf Bruns, Siemens AG
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12712049

ANTIBODIES THAT BIND TGF-ALPHA AND EPIREGULIN

IPC classification:
A61K 39/00, C07K 16/22
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13726321

ANTI-BAFF-ANTI-IL-17 BISPECIFIC ANTIBODIES

IPC classification:
C07K 16/24, C07K 16/28, C07K 16/46
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
PATENT GRANTED
EP13712005

2-AMINO, 6-PHENYL SUBSTITUTED PYRIDO [2, 3 - D]PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS

IPC classification:
A61K 31/519, A61P 35/00, C07D 471/04, C07D 471/12
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13724685

THERAPEUTIC USES OF FIBROBLAST GROWTH FACTOR 21 PROTEINS

IPC classification:
A61K 38/18, A61P 19/08, A61P 19/10
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
EXAMINATION IN PROGRESS
EP12783780

CARBOLINE AND CARBAZOLE BASED IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION

IPC classification:
A61K 49/10, A61K 51/04, C07B 59/00, C07D 209/88, C07D 403/12, C07D 471/04, C07D 471/14
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP13730733

FIBROBLAST GROWTH FACTOR 21 PROTEINS

IPC classification:
A61K 38/18, C07K 14/50
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
GRANT OF PATENT INTENDED
EP13729210

FIBROBLAST GROWTH FACTOR 21 VARIANTS

IPC classification:
A61K 38/18, C07K 14/50
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
PATENT GRANTED
EP13802786

6-((S)-1-{1-[5-(2-HYDROXY-ETHOXY)-PYRIDIN-2-YL]-1H-PYRAZOL-3-YL}-ETHYL)-3H-1,3-BENZOTHIAZOL-2-ONE AS A TARP-GAMMA 8 DEPENDENT AMPA RECEPTOR ANTAGONIST

IPC classification:
A61K 31/4439, A61P 25/04, A61P 25/08, C07D 417/14
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
PATENT GRANTED
EP13765974

PREPARATION OF LIVE VACCINES

IPC classification:
A61K 39/02, A61K 39/112, C12R 1/42
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
GRANT OF PATENT INTENDED
EP13818045

BMP-6 ANTIBODIES

IPC classification:
A61K 39/395, A61P 7/06, C07K 16/22
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
PATENT GRANTED
EP14761062

ANTIBODIES THAT BIND IL-23

IPC classification:
A61K 39/395
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP14719931

METHODS FOR PRODUCING FABS AND BI-SPECIFIC ANTIBODIES

IPC classification:
C07K 16/00
Applicant:
Eli Lilly and Company Limited
Applicant:
The University of North Carolina at Chapel Hill
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
EXAMINATION IN PROGRESS
EP14722408

THERAPEUTIC USES FOR VEGFR1 ANTIBODIES

IPC classification:
A61K 39/395, A61P 13/12, C07K 16/28
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
EXAMINATION IN PROGRESS
EP14783708

COMPOUNDS AND THEIR USE FOR PREPARATION OF TAU IMAGING AGENTS AND TAU IMAGING FORMULATIONS

IPC classification:
A61K 31/437, A61P 25/28, C07D 471/04, G01N 33/68
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
EXAMINATION IN PROGRESS
EP11754805

ANTI-VEGFR-3 ANTIBODY COMPOSITIONS

IPC classification:
C07K 16/28
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP14824266

COMPOUNDS TO FIBROBLAST GROWTH FACTOR RECEPTOR-3 (FGFR3) AND THERAPEUTIC USES

IPC classification:
A61K 31/559, A61K 47/48, A61P 35/00, C07K 16/28, G01N 33/574
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
EXAMINATION IN PROGRESS
EP15709024

ANTI-MET IN COMBINATION WITH ANTI-VEGFR2 ANTIBODIES THERAPY FOR CANCER

IPC classification:
A61K 39/395, A61P 35/00, C07K 16/28, C07K 16/30
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP15724469

VEGFR2/ANG2 COMPOUNDS

IPC classification:
A61K 39/395, A61P 35/00, C07K 16/22, C07K 16/28, C07K 16/46
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP15796232

ANG2 ANTIBODIES

IPC classification:
A61K 39/395
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP15726843

6-SUBSTITUTED-3H-1,3-BENZOTHIAZOL-2-ONE COMPOUNDS AS TARP-GAMMA 8 DEPENDENT AMPA RECEPTOR ANTAGONISTS

IPC classification:
A61K 31/41, A61P 25/00, C07D 417/14
Applicant:
Eli Lilly and Company Limited
Agent:
Toby Gosnall, Barker Brettell LLP
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP16196811

ANTIBODIES AGAINST CSF-1R

IPC classification:
A61K 39/00, A61K 39/395, A61K 45/06, A61P 35/00, A61P 35/02, C07K 16/28, C07K 16/32
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
Request for examination was made
EP15754347

ANTI-VEGFR2 ANTIBODY THERAPY FOR HEPATOCELLULAR CARCINOMA

IPC classification:
A61K 39/395, A61P 35/00, C07K 16/28, C07K 16/30, G01N 33/574
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP17153380

ANTI-BAFF-ANTI-IL-17 BISPECIFIC ANTIBODIES

IPC classification:
C07K 16/24, C07K 16/28, C07K 16/46
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
The application has been published
EP15791228

ANTI-TNF-/ANTI-IL-23 BISPECIFIC ANTIBODIES

IPC classification:
A61K 39/00, A61K 39/395, C07K 16/24, C07K 16/28
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
Request for examination was made
EP16704512

IgG BISPECIFIC ANTIBODIES AND PROCESSES FOR PREPARATION

IPC classification:
C07K 16/00, C07K 16/28, C07K 16/32
Applicant:
Eli Lilly and Company Limited
Applicant:
The University of North Carolina at Chapel Hill
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
Request for examination was made
EP16703684

VEGFA/ANG2 COMPOUNDS

IPC classification:
A61K 39/395, A61P 27/02, A61P 35/00, C07K 16/22
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
Request for examination was made

Please Sign in to use this feature